Progress with pathogen-reduced blood

SAFETY OF BLOOD AND PLASMA DERIVATIVES: PATHOGEN REDUCING TECHNOLOGIES

   ABSTRACT  Human blood and blood products is the source of a wide range of medicinal products used for the treatment and prevention of a variety of injuries and disease. Despite stringent routine measures and filters employed, residual pathogen infectivity remains an important challenge in the field of blood transfusion. In this article various measures and technologies that can be applied in...

Blood hyperviscosity with reduced skin blood flow in scleroderma.

The vascular complications of scleroderma have previously been attributed to the progressive obliteration of small vessels. Our study was carried out to determine whether abnormalities of blood viscosity occur in this disease, thereby contributing to the ischaemic process. Blood viscosity was measured in 20 patients using a rotational viscometer. At a high rate of shear, blood hyperviscosity wa...

Progress in Computational Studies of Host-pathogen Interactions

Host-pathogen interactions are important for understanding infection mechanism and developing better treatment and prevention of infectious diseases. Many computational studies on host-pathogen interactions have been published. Here, we review recent progress and results in this field and provide a systematic summary, comparison and discussion of computational studies on host-pathogen interacti...

safety of blood and plasma derivatives: pathogen reducing technologies

abstract human blood and blood products is the source of a wide range of medicinal products used for the treatment and prevention of a variety of injuries and disease. despite stringent routine measures and filters employed, residual pathogen infectivity remains an important challenge in the field of blood transfusion. in this article various measures and technologies that can be applied in ord...

Reduced LV myocardial blood flow.